An interventional study of Concurrent Training and Soleus Push-ups in Diabetic Peripheral Neuropathy Type 2, sponsored by Riphah International University. Not yet recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Riphah International University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Diabetic Neuropathies by Riphah International University — 7 open to participants now, 7 under way, none of them phase 3. Diabetic Neuropathies · Riphah International University.
Among the 24 studies in Diabetic Neuropathies by Riphah International University, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 24 with no phase, and was the 22nd registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →7 of the 24 studies in Diabetic Neuropathies by Riphah International University are open now, in 1 country. Recruiting first, the newest first:
Riphah International University · Sites in Pakistan
Ages 40 mo–75 mo
Riphah International University · Sites in Pakistan
Ages 45–67
Riphah International University
Ages 18+
Riphah International University · Sites in Pakistan
Ages 18+
Riphah International University · Sites in Pakistan
Ages 45–65
By country, each count listing its studies:
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 40 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 99 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 44 across the 24 interventional studies. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Riphah International University is the lead sponsor of 2,201 studies on the registry; 647 are open to participants now.
3 of the studies in Diabetic Neuropathies by Riphah International University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07619755Riphah International UniversitytSCS and AR Training on QoL and Physical Activity in Diabetic Neuropathy Patients | 2026-12-31 |
| NCT07619794Riphah International UniversitytSCS and AR on Pain and Balance in Diabetic Peripheral Neuropathy | 2026-12-31 |
| NCT07675720Riphah International UniversityConcurrent Training vs Soleus Push-Ups on Neurogenesis-Related Biomarkers in Diabetic Neuropathy Patients | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Diabetic Neuropathies by Riphah International University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine how two types of exercise programs affect nerve health in people with diabetic peripheral neuropathy. Diabetic peripheral neuropathy is a common complication of type 2 diabetes that can cause numbness, pain, balance problems, and reduced quality of life. Exercise is often recommended for people with diabetes, but it is not yet clear which types of exercise are most effective for improving nerve function.
In this randomized controlled trial, participants with type 2 diabetes and confirmed peripheral neuropathy will be assigned to one of three groups. One group will perform a combined program of aerobic and resistance exercises (concurrent training). Another group will perform soleus push-up exercises, a seated ankle movement designed to activate the soleus muscle and improve glucose metabolism. The third group will continue with standard diabetes care and general lifestyle advice without a structured exercise program.
The study will evaluate whether these exercise interventions influence biological markers related to nerve repair and neuroplasticity, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and the Schwann cell marker S100B. In addition, the study will assess changes in neuropathy symptoms, balance and postural stability, blood sugar control, and quality of life.
Participants will complete assessments before the intervention and again during follow-up after the exercise program. The findings of this study may help identify effective and feasible exercise strategies to support nerve health, improve physical function, and reduce the impact of diabetic peripheral neuropathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis is based on clinical evaluation and scoring tools such as:
Vibration Pressure Threshold (≥25 Volts)(106)
Exclusion Criteria:
History of recent cardiovascular events Includes myocardial infarction, stroke, or any cardiac intervention within the past 6 months.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo a combined aerobic and resistance exercise program.
Other: Concurrent Training
Participants will perform seated plantar-flexion exercises targeting the soleus muscle, using a controlled movement protocol modeled after the soleus push-up method.
Other: Soleus Push-ups
Participants will receive standard diabetes care and general lifestyle advice without structured exercise intervention.
Combined aerobic and resistance exercise program.
Also known as: Exercise
Seated plantar-flexion exercises targeting the soleus muscle, using a controlled movement protocol
Also known as: Exercise
BDNF (Brain-Derived Neurotrophic Factor)
Serum Brain-Derived Neurotrophic Factor (BDNF) concentration will be measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) kit at baseline, 4 weeks, and 8 weeks. BDNF is a neurotrophic factor involved in neuronal survival, synaptic plasticity, and exercise-induced neuroplasticity. Changes in circulating BDNF levels will be used as a primary biomarker of exercise-induced neuroplasticity and neurogenesis-related biological activity. Higher serum BDNF concentrations are considered indicative of greater neurotrophic activity and potential enhancement of neuroplastic processes.
Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.
NGF (Nerve Growth Factor)
Serum Nerve Growth Factor (NGF) concentration will be measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) kit at baseline, 4 weeks, and 8 weeks. NGF is a key neurotrophic factor involved in the survival, maintenance, and regeneration of peripheral neurons. It plays a fundamental role in peripheral nerve repair and axonal regeneration following nerve injury. Changes in circulating NGF levels will be used as a primary biomarker of peripheral nerve regeneration and neuroregeneration-related biological activity. Higher serum NGF concentrations are considered indicative of enhanced neurotrophic support and regenerative potential of peripheral nerves.
Time frame: From enrollement to 4 weeks and then after 8 weeks of intervention
S100B (Schwann Cell Marker)
Serum S100 Calcium-Binding Protein B (S100B) concentration will be measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) kit at baseline, 4 weeks, and 8 weeks. S100B is a calcium-binding protein that is expressed by Schwann cells in the peripheral nervous system and plays an important role in peripheral nerve repair, remyelination, and axonal regeneration. Changes in circulating S100B levels will be used as a primary biomarker of Schwann cell activity and peripheral nerve regeneration. Higher serum S100B concentrations are considered indicative of increased Schwann cell-mediated neuroregenerative activity.
Time frame: From enrollment to 4 weeks and then after 8 weeks of intervention
Michigan Neuropathy Screening Instrument (MNSI)
Neuropathy severity will be assessed using the Michigan Neuropathy Screening Instrument (MNSI), a validated instrument for screening and evaluating diabetic peripheral neuropathy. The MNSI consists of two components: (1) a 15-item patient-reported symptom questionnaire (History; Part A) and (2) a standardized physical examination (Part B) that assesses foot appearance, ulceration, ankle reflexes, and vibration sensation. Assessments will be performed at baseline, 4 weeks, and 8 weeks. The MNSI History score ranges from 0 to 13, with a score of ≥4 indicating the presence of diabetic peripheral neuropathy. The MNSI Examination score ranges from 0 to 8, with a score of ≥2 considered diagnostic of diabetic peripheral neuropathy. Higher scores on both components indicate greater neuropathy severity, whereas lower scores following the intervention indicate improvement in peripheral nerve function and neuropathic symptoms.
Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.
Vibration perception threshold (VPT)
Vibration perception threshold will be assessed using a digital biothesiometer to evaluate large-fiber peripheral nerve function in participants with diabetic peripheral neuropathy. The biothesiometer measures the minimum vibration intensity perceived by the participant and is recorded in volts (V). Assessments will be performed at baseline, 4 weeks, and 8 weeks. The VPT score ranges from 0 to 50 volts, with higher values indicating poorer vibration perception and more severe peripheral nerve dysfunction. A VPT value of ≥25 volts will be used as the diagnostic threshold for diabetic peripheral neuropathy. A reduction in VPT values following the intervention indicates improved sensory nerve function and reduced neuropathy severity.
Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.
Balance and Gait Mobile Application
Balance and gait performance will be assessed using the validated Balance and Gait mobile application. The application utilizes the smartphone's built-in inertial sensors (accelerometer and gyroscope) to objectively evaluate postural stability and gait performance. Assessments will be conducted at baseline, 4 weeks, and 8 weeks. The application provides quantitative measures of balance and gait, including postural sway, gait stability, walking speed, cadence, stride characteristics, and an overall balance/gait performance score, depending on the application outputs. Higher balance and gait scores (or improved gait parameters, such as increased gait speed and reduced postural sway) indicate better functional mobility and postural stability, whereas poorer scores indicate greater balance impairment and increased risk of falls.
Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.
Glycated Hemoglobin (HbA1c)
Glycated hemoglobin (HbA1c) will be measured using a standardized laboratory assay to assess long-term glycemic control. HbA1c reflects the average blood glucose concentration over the preceding 2-3 months and is reported as a percentage (%) of total hemoglobin. Assessments will be performed at baseline, 4 weeks, and 8 weeks. HbA1c values range from approximately 4% to 14% or higher, with lower values indicating better glycemic control. In accordance with the American Diabetes Association (ADA) criteria, an HbA1c level of \<5.7% is considered normal, 5.7%-6.4% indicates prediabetes, and ≥6.5% is diagnostic of diabetes mellitus. Participants eligible for this study will have baseline HbA1c values between 6.5% and 9.0%. A reduction in HbA1c following the intervention will indicate improved long-term glycemic control.
Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.
Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN)
Health-related quality of life will be assessed using the Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) questionnaire, a validated patient-reported outcome measure specifically designed to evaluate the impact of diabetic peripheral neuropathy on physical functioning and quality of life. The questionnaire assesses symptoms and functional limitations across multiple domains, including physical functioning/large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. Assessments will be conducted at baseline, 4 weeks, and 8 weeks. The Norfolk QOL-DN total score ranges from -4 to 136, with higher scores indicating poorer health-related quality of life and greater neuropathy-related impairment, whereas lower scores indicate better quality of life and reduced symptom burden. A decrease in the total score following the intervention will be interprete
Time frame: From enrollment to 4 weeks and then to the end of treatment at 8 weeks.
Acceptability of Intervention Measure (AIM)
Acceptability of the exercise intervention will be assessed using the Acceptability of Intervention Measure (AIM), a validated implementation outcome instrument. The AIM consists of 4 items rated on a 5-point Likert scale ranging from 1 (Completely Disagree) to 5 (Completely Agree), yielding a total score of 4-20. Higher scores indicate greater participant-perceived acceptability of the intervention. The AIM will be administered at the completion of the 8-week intervention.
Time frame: At the end of treatment at 8 weeks.
Intervention Appropriateness Measure (IAM)
Perceived appropriateness of the exercise intervention will be assessed using the Intervention Appropriateness Measure (IAM). The IAM consists of 4 items rated on a 5-point Likert scale ranging from 1 (Completely Disagree) to 5 (Completely Agree), resulting in a total score of 4-20. Higher scores indicate that participants perceive the intervention to be more appropriate and suitable for managing diabetic peripheral neuropathy. The IAM will be administered at the completion of the 8-week intervention.
Time frame: At the end of treatment after 8 weeks of intervention
Feasibility of Intervention Measure (FIM)
Feasibility of the exercise intervention will be evaluated using the Feasibility of Intervention Measure (FIM). The FIM consists of 4 items rated on a 5-point Likert scale ranging from 1 (Completely Disagree) to 5 (Completely Agree), yielding a total score of 4-20. Higher scores indicate greater perceived feasibility of implementing the intervention in clinical practice. The FIM will be administered at the completion of the 8-week intervention.
Time frame: At the end of treatment after 8 weeks of intervention.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Individual participant data collected during the trial will not be made publicly available. Study findings will be disseminated through peer-reviewed publications and conference presentations. All data will remain securely stored by the research team in accordance with institutional policies and ethical guidelines.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 138 non-industry interventional studies with no phase under Diabetic Neuropathies, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 12 months is close to that.
Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 6 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Riphah International University →